Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases

Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12 C-mutated non-small cell lung cancer (NSCLC).